Table 2 Clincal demograchics of EGFR-mutant patients regarding different treatment modalities.
Characteristics | All (N = 50) | CTONG1103-GDLC cohort | Multi-center cohorts | P-value | |
|---|---|---|---|---|---|
GC (n = 15) | Erlotinib (n = 16) | IO + CT (n = 19) | |||
Age at diagnosis (y), mean (SD) | 60.2 (10.2) | 61.1 (11.0) | 57.1 (12.5) | 62.2 (9.8) | 0.315 (T-test) |
Gender, n (%) | 0.775 (Chisq) | ||||
Male | 18 (36.0) | 5 (33.3) | 5 (31.2) | 8 (42.1) | |
Female | 32 (64.0) | 10 (66.7) | 11 (68.8) | 11 (57.9) | |
Smoking status, n (%) | 0.247 (Fisher) | ||||
Never | 40 (80.0) | 14 (93.3) | 11 (68.8) | 15 (78.9) | |
Former | 10 (20.0) | 1 (6.7) | 5 (31.2) | 4 (21.1) | |
Histology, n (%) | 0.709 (Chisq) | ||||
Adenocarcinoma | 45 (90.0) | 14 (93.3) | 13 (81.3) | 18 (94.7) | |
Squamous | 4 (8.0) | 1 (6.7) | 2 (12.5) | 1 (5.3) | |
Others | 1 (2.0) | 0 (0) | 1 (6.2) | 0 (0) | |
TNM stage, n (%) | 0.084 (Chisq) | ||||
II | 4 (8.0) | 0 (0) | 0 (0) | 4 (21.1) | |
IIIA | 34 (68.0) | 9 (60.0) | 13 (81.3) | 12 (63.1) | |
IIIB | 12 (24.0) | 6 (40.0) | 3 (18.7) | 3 (15.8) | |
EGFR mutation, n (%) | 0.082 (Fisher) | ||||
Exon 19Del | 17 (34.0) | 6 (40.0) | 5 (31.2) | 6 (31.6) | |
Exon 21L858R | 28 (56.0) | 9 (60.0) | 11 (68.8) | 8 (42.1) | |
Insertion | 5 (10.0) | 0 (0) | 0 (0) | 5 (26.3) | |
